Go to deals
Healthcare

Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Shield is a de-risked, specialty pharmaceutical company focused on commercializing its lead product, Feraccru®/Accrufer®, a novel, non-salt-based oral therapy for adults with iron deficiency with or without anemia.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as the joint broker on this transaction.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Geoff  Nash

Geoff Nash

Partner
London, United Kingdom
Oaklins Cavendish

Related deals

DierenDokters has been acquired by VetPartners
Consumer & Retail | Healthcare | Private Equity

DierenDokters has been acquired by VetPartners

DierenDokters, a leading group of fourteen veterinary clinics located across the Netherlands, has been acquired by VetPartners, a UK-based group of over 650 veterinary clinics and hospitals located across Europe. By partnering with VetPartners, DierenDokters welcomes a strong new shareholder that will help further enhance DierenDokters’ clinics’ service offering and allow the clinics to continue focusing on providing the best possible animal healthcare services.

Learn more
Connexicon Medical has been acquired by Advanced Medical Solutions PLC
Healthcare

Connexicon Medical has been acquired by Advanced Medical Solutions PLC

Connexicon Medical Ltd has been sold to Advanced Medical Solutions PLC.

Learn more
Therapy Equipment has been acquired by ESAB Corporation
Healthcare | Private Equity

Therapy Equipment has been acquired by ESAB Corporation

Owner Venture Managers has sold Therapy Equipment Ltd. to ESAB Corporation.

Learn more